Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0V2ZC
|
|||
Drug Name |
SEL24
|
|||
Synonyms |
MEN1703
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1/2 | [1] | |
Company |
Menarini
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Fms-like tyrosine kinase 3 (FLT-3) | Target Info | Inhibitor | [2] |
Serine/threonine-protein kinase pim (PIM) | Target Info | Inhibitor | [2] | |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
Hematopoietic cell lineage | ||||
Pathways in cancer | ||||
Transcriptional misregulation in cancer | ||||
Acute myeloid leukemia | ||||
Central carbon metabolism in cancer |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03008187) SEL24/MEN1703 in Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health. | |||
REF 2 | A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018 Mar 30;9(24):16917-16931. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.